DACOMITINIB (PF-00299804), AN IRREVERSIBLE PAN-HER TYROSINE KINASE INHIBITOR (TKI), FOR FIRST-LINE TREATMENT OF EGFR-MUTANT OR HER2-MUTANT OR -AMPLIFIED LUNG CANCERS
Other conference paper


Full Text

Times Cited
Web of Science14WOS source URL (as at 18/09/2021) Click here for the latest count

Other information
All Author(s) ListKris M, Goldberg Z, Janne PA, Kim D, Martins R, Mok TSK, O'Connell J, Ou S, Taylor I, Zhang H
Name of Conference37th Congress of the European-Society-for-Medical-Oncology (ESMO)
Start Date of Conference28/09/2012
End Date of Conference02/10/2012
Place of ConferenceVienna
Country/Region of ConferenceAustria
Journal nameAnnals of Oncology
Detailed descriptionorganized by European Society for Medical Oncology,
Year2012
Month9
Day1
Volume Number23
PublisherOxford University Press (OUP): Policy B - Oxford Open Option B - CC-BY
Pages401 - 402
ISSN0923-7534
eISSN1569-8041
LanguagesEnglish-United Kingdom
Web of Science Subject CategoriesOncology; ONCOLOGY

Last updated on 2021-18-09 at 23:47